Probiotics:: towards demonstrating efficacy

被引：69
作者：
Mattila-Sandholm, T
Blum, S
Collins, JK
Crittenden, R
de Vos, W
Dunne, C
Fondén, R
Grenov, G
Isolauri, E
Kiely, B
Marteau, P
Morelli, L
Ouwehand, A
Reniero, R
Saarela, M
Salminen, S
Saxelin, M
Schiffrin, E
Shanahan, F
Vaughan, E
von Wright, A
机构：
[1] VTT Biotechnol, FIN-02044 Espoo, Finland
[2] Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland
[3] Univ Coll Cork, Dept Microbiol, Cork, Ireland
[4] Univ Coll Cork, Dept Med, Cork, Ireland
[5] Natl Food Biotechnol Ctr, Cork, Ireland
[6] Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands
[7] ARLA R&D, S-10546 Stockholm, Sweden
[8] Chr Hansen AS, DK-2970 Horsholm, Denmark
来源：
TRENDS IN FOOD SCIENCE & TECHNOLOGY | 1999年 / 10卷 / 12期
关键词：
D O I：
10.1016/S0924-2244(00)00029-7
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
PROBDEMO, a multi-centre European research project, began in 1996 with the aim of demonstrating that probiotic microorganisms can positively effect human health in rigorously conducted human clinical studies. These studies, now completed, have shown that some probiotics can influence the composition of the intestinal microbiota and modulate the host immune system with measurable benefits to health, including the control of atopic eczema in infants with food allergy. Considerable promise was also demonstrated for the use of selected probiotics in controlling inflammatory bowel disease, and infections in children and the elderly. The scientific approaches to selecting and evaluating probiotics that were demonstrated in the PROBDEMO project provide a model for food manufacturers to move further towards demonstrating efficacy for their probiotic products. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：393 / 399
页数：7
相关论文
共 30 条
[1]  
Aiba Y, 1998, AM J GASTROENTEROL, V93, P2097, DOI 10.1111/j.1572-0241.1998.00600.x
[2]   Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections:: A randomized study [J].
Arvola, T ;
Laiho, K ;
Torkkeli, S ;
Mykkänen, H ;
Salminen, S ;
Maunula, L ;
Isolauri, E .
PEDIATRICS, 1999, 104 (05) :art. no.-e64
[3]  
Coconnier MH, 1998, APPL ENVIRON MICROB, V64, P4573
[4]   Colonic bacteria express an ulcerative colitis pANCA-related protein epitope [J].
Cohavy, O ;
Bruckner, D ;
Gordon, LK ;
Misra, R ;
Wei, B ;
Eggena, ME ;
Targan, SR ;
Braun, J .
INFECTION AND IMMUNITY, 2000, 68 (03) :1542-1548
[5]   Modulation of nonspecific mechanisms of defense by lactic acid bacteria: Effective dose [J].
Donnet-Hughes, A ;
Rochat, F ;
Serrant, P ;
Aeschlimann, JM ;
Schiffrin, EJ .
JOURNAL OF DAIRY SCIENCE, 1999, 82 (05) :863-869
[6]   Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials [J].
Dunne, C ;
Murphy, L ;
Flynn, S ;
O'Mahony, L ;
O'Halloran, S ;
Feeney, M ;
Morrissey, D ;
Thornton, G ;
Fitzgerald, G ;
Daly, C ;
Kiely, B ;
Quigley, EMM ;
O'Sullivan, GC ;
Shanahan, F ;
Collins, JK .
ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 1999, 76 (1-4) :279-292
[7]  
FULLER R, 1989, J APPL BACTERIOL, V66, P365
[8]   Gut flora allows recovery of oral tolerance to ovalbumin in mice after transient breakdown mediated by cholera toxin or Escherichia coli heat-labile enterotoxin [J].
GaboriauRouthiau, V ;
Moreau, MC .
PEDIATRIC RESEARCH, 1996, 39 (04) :625-629
[9]   Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea:: A multicenter European trial [J].
Guandalini, S ;
Pensabene, L ;
Abu Zikri, M ;
Dias, JA ;
Casali, LG ;
Hoekstra, H ;
Kolacek, S ;
Massar, K ;
Micetic-Turk, D ;
Papadopoulou, A ;
de Sousa, JS ;
Sandhu, B ;
Szajewska, H ;
Weizman, Z .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2000, 30 (01) :54-60
[10]   Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model [J].
Kabir, AMA ;
Aiba, Y ;
Takagi, A ;
Kamiya, S ;
Miwa, T ;
Koga, Y .
GUT, 1997, 41 (01) :49-55
123